Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of parkinson disease
Identifieur interne : 002693 ( Main/Exploration ); précédent : 002692; suivant : 002694Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of parkinson disease
Auteurs : Joseph Flores [Canada] ; Ivan L. Cepeda [Canada] ; Michael L. Comfeldt [États-Unis] ; John R. O'Kusky [Canada] ; Doris J. Doudet [Canada]Source :
- Journal of neuropathology and experimental neurology [ 0022-3069 ] ; 2007.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Animals, Cell Survival, Cell Transplantation (methods), Characterization, Corpus Striatum (pathology), Corpus Striatum (physiopathology), Corpus Striatum (surgery), Disease Models, Animal, Epithelial cell, Gelatin (therapeutic use), Human, Humans, Immunohistochemistry, Implant, Long term, Male, Microscopy, Electron, Transmission (methods), Microspheres, Models, Nerve Tissue Proteins (metabolism), Nervous system diseases, Parkinson Disease (etiology), Parkinson Disease (physiopathology), Parkinson Disease (surgery), Parkinson disease, Pigment Epithelium of Eye (physiology), Pigment Epithelium of Eye (transplantation), Pigment Epithelium of Eye (ultrastructure), Pigment cell, Rats, Rats, Sprague-Dawley, Retina, Survival, Time Factors, Transplantation, Transplantation, Heterologous (methods).
- MESH :
- chemical , metabolism : Nerve Tissue Proteins.
- chemical , therapeutic use : Gelatin.
- etiology : Parkinson Disease.
- methods : Cell Transplantation, Microscopy, Electron, Transmission, Transplantation, Heterologous.
- pathology : Corpus Striatum.
- physiology : Pigment Epithelium of Eye.
- physiopathology : Corpus Striatum, Parkinson Disease.
- surgery : Corpus Striatum, Parkinson Disease.
- transplantation : Pigment Epithelium of Eye.
- ultrastructure : Pigment Epithelium of Eye.
- Animals, Cell Survival, Disease Models, Animal, Humans, Male, Microspheres, Rats, Rats, Sprague-Dawley, Time Factors.
Abstract
Previous studies have demonstrated that the intrastriatal implantation of human retinal pigment epithelial cells attached to gelatin microcarriers (hRPE-GM) ameliorates behavioral deficits in animal models of Parkinson disease. However, there are only sparse data on cell survival in the host. In this study, we characterized a variety of retinal pigment epithelial (RPE)-specific markers in vitro and used these markers to investigate the long-term survival of hRPE-GM implants. Sprague-Dawley rats (n = 22) were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) and implanted with hRPE-GM without immunosuppression. Rats were euthanized at 48 hours, 7 days, 4 weeks, and 5 months postimplant and immunohistochemically processed using the following antibodies: 1) human-specific nuclear mitotic apparatus protein (NuMA-Ab2), 2) epithelial-specific extracellular matrix metalloproteinase inducer (EMM-PRIN), 3) RPE cell-specific RPE65, and the inflammation markers 4) glial fibrillary acidic protein and 5) ED1 (rat CD68). Our analysis revealed NuMA-, EMMPRIN-, and RPE65-immunoreactive cells at different times postimplant. The morphologic features of hRPE cell implants (at 48 hours and 5 months) were confirmed by electron microscopy. Furthermore, despite evidence of chronic inflammation at the later time point, there is an appreciable number of surviving hRPE cells. This study suggests that hRPE-GM implants can survive in the absence of immunosuppression and can be potentially used as an alternative for treating Parkinson disease.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000722
- to stream PascalFrancis, to step Curation: 000598
- to stream PascalFrancis, to step Checkpoint: 000668
- to stream Main, to step Merge: 002958
- to stream PubMed, to step Corpus: 001059
- to stream PubMed, to step Curation: 001059
- to stream PubMed, to step Checkpoint: 001059
- to stream Ncbi, to step Merge: 000788
- to stream Ncbi, to step Curation: 000788
- to stream Ncbi, to step Checkpoint: 000788
- to stream Main, to step Merge: 002721
- to stream Main, to step Curation: 002693
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of parkinson disease</title><author><name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine/Neurology, Pacific Parkinson Research Centre, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L." last="Cepeda">Ivan L. Cepeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine/Neurology, Pacific Parkinson Research Centre, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Comfeldt, Michael L" sort="Comfeldt, Michael L" uniqKey="Comfeldt M" first="Michael L." last="Comfeldt">Michael L. Comfeldt</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Cell Therapy Titan Pharmaceuticals, Inc</s1><s2>Somerville, New Jersey</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R." last="O'Kusky">John R. O'Kusky</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pathology and Laboratory Medicine, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J." last="Doudet">Doris J. Doudet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine/Neurology, Pacific Parkinson Research Centre, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0349206</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0349206 INIST</idno><idno type="RBID">Pascal:07-0349206</idno><idno type="wicri:Area/PascalFrancis/Corpus">000722</idno><idno type="wicri:Area/PascalFrancis/Curation">000598</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000668</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000668</idno><idno type="wicri:doubleKey">0022-3069:2007:Flores J:characterization:and:survival</idno><idno type="wicri:Area/Main/Merge">002958</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17620984</idno><idno type="wicri:Area/PubMed/Corpus">001059</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001059</idno><idno type="wicri:Area/PubMed/Curation">001059</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001059</idno><idno type="wicri:Area/PubMed/Checkpoint">001059</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001059</idno><idno type="wicri:Area/Ncbi/Merge">000788</idno><idno type="wicri:Area/Ncbi/Curation">000788</idno><idno type="wicri:Area/Ncbi/Checkpoint">000788</idno><idno type="wicri:doubleKey">0022-3069:2007:Flores J:characterization:and:survival</idno><idno type="wicri:Area/Main/Merge">002721</idno><idno type="wicri:Area/Main/Curation">002693</idno><idno type="wicri:Area/Main/Exploration">002693</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of parkinson disease</title><author><name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine/Neurology, Pacific Parkinson Research Centre, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L." last="Cepeda">Ivan L. Cepeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine/Neurology, Pacific Parkinson Research Centre, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Comfeldt, Michael L" sort="Comfeldt, Michael L" uniqKey="Comfeldt M" first="Michael L." last="Comfeldt">Michael L. Comfeldt</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Cell Therapy Titan Pharmaceuticals, Inc</s1><s2>Somerville, New Jersey</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R." last="O'Kusky">John R. O'Kusky</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pathology and Laboratory Medicine, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J." last="Doudet">Doris J. Doudet</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Medicine/Neurology, Pacific Parkinson Research Centre, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver, British Columbia</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of neuropathology and experimental neurology</title><title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title><idno type="ISSN">0022-3069</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of neuropathology and experimental neurology</title><title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title><idno type="ISSN">0022-3069</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cell Survival</term><term>Cell Transplantation (methods)</term><term>Characterization</term><term>Corpus Striatum (pathology)</term><term>Corpus Striatum (physiopathology)</term><term>Corpus Striatum (surgery)</term><term>Disease Models, Animal</term><term>Epithelial cell</term><term>Gelatin (therapeutic use)</term><term>Human</term><term>Humans</term><term>Immunohistochemistry</term><term>Implant</term><term>Long term</term><term>Male</term><term>Microscopy, Electron, Transmission (methods)</term><term>Microspheres</term><term>Models</term><term>Nerve Tissue Proteins (metabolism)</term><term>Nervous system diseases</term><term>Parkinson Disease (etiology)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (surgery)</term><term>Parkinson disease</term><term>Pigment Epithelium of Eye (physiology)</term><term>Pigment Epithelium of Eye (transplantation)</term><term>Pigment Epithelium of Eye (ultrastructure)</term><term>Pigment cell</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Retina</term><term>Survival</term><term>Time Factors</term><term>Transplantation</term><term>Transplantation, Heterologous (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Nerve Tissue Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Gelatin</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cell Transplantation</term><term>Microscopy, Electron, Transmission</term><term>Transplantation, Heterologous</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Pigment Epithelium of Eye</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Pigment Epithelium of Eye</term></keywords><keywords scheme="MESH" qualifier="ultrastructure" xml:lang="en"><term>Pigment Epithelium of Eye</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Survival</term><term>Disease Models, Animal</term><term>Humans</term><term>Male</term><term>Microspheres</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Caractérisation</term><term>Survie</term><term>Long terme</term><term>Implant</term><term>Homme</term><term>Rétine</term><term>Cellule pigmentaire</term><term>Cellule épithéliale</term><term>Modèle</term><term>Immunohistochimie</term><term>Transplantation</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous studies have demonstrated that the intrastriatal implantation of human retinal pigment epithelial cells attached to gelatin microcarriers (hRPE-GM) ameliorates behavioral deficits in animal models of Parkinson disease. However, there are only sparse data on cell survival in the host. In this study, we characterized a variety of retinal pigment epithelial (RPE)-specific markers in vitro and used these markers to investigate the long-term survival of hRPE-GM implants. Sprague-Dawley rats (n = 22) were unilaterally lesioned with 6-hydroxydopamine (6-OHDA) and implanted with hRPE-GM without immunosuppression. Rats were euthanized at 48 hours, 7 days, 4 weeks, and 5 months postimplant and immunohistochemically processed using the following antibodies: 1) human-specific nuclear mitotic apparatus protein (NuMA-Ab2), 2) epithelial-specific extracellular matrix metalloproteinase inducer (EMM-PRIN), 3) RPE cell-specific RPE65, and the inflammation markers 4) glial fibrillary acidic protein and 5) ED1 (rat CD68). Our analysis revealed NuMA-, EMMPRIN-, and RPE65-immunoreactive cells at different times postimplant. The morphologic features of hRPE cell implants (at 48 hours and 5 months) were confirmed by electron microscopy. Furthermore, despite evidence of chronic inflammation at the later time point, there is an appreciable number of surviving hRPE cells. This study suggests that hRPE-GM implants can survive in the absence of immunosuppression and can be potentially used as an alternative for treating Parkinson disease.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>New Jersey</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Flores, Joseph" sort="Flores, Joseph" uniqKey="Flores J" first="Joseph" last="Flores">Joseph Flores</name></noRegion><name sortKey="Cepeda, Ivan L" sort="Cepeda, Ivan L" uniqKey="Cepeda I" first="Ivan L." last="Cepeda">Ivan L. Cepeda</name><name sortKey="Doudet, Doris J" sort="Doudet, Doris J" uniqKey="Doudet D" first="Doris J." last="Doudet">Doris J. Doudet</name><name sortKey="O Kusky, John R" sort="O Kusky, John R" uniqKey="O Kusky J" first="John R." last="O'Kusky">John R. O'Kusky</name></country><country name="États-Unis"><region name="New Jersey"><name sortKey="Comfeldt, Michael L" sort="Comfeldt, Michael L" uniqKey="Comfeldt M" first="Michael L." last="Comfeldt">Michael L. Comfeldt</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002693 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002693 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0349206
|texte= Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of parkinson disease
}}
| This area was generated with Dilib version V0.6.29. |  |